RxDoctor Payments Data

Michael Borofsky, MD

Urology · Indianapolis, INNPI 1629202197

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 46.3% of the total. Reporting peaked in 2019 at $97,856 and has fallen 82.2% since, to $17,442 in 2025. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$243,884in general payments, 2019–2025

Across 158 payments — averaging $1543.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$113K
  • Boston Scientific$98K
  • Laborie Medical Technologies Corp.$21K
  • KARL Storz Endoscopy-america$5K
  • GE HealthCare$3K
  • Auris Health, Inc.$3K
  • plus $2K from 3 others
$2,400in research payments, 2019–2025

Across 1 payment — averaging $2400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Urotronic, Inc$2K

What the payments were for

  • Consulting fees$117,73248%
  • Speaking & faculty fees$118,05948%
  • Travel & lodging$5,4082%
  • Food & beverage$2,1731%
  • Education$5120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$243,884 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$69,983
Medicare patients
170
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin24$183,161
MyrbetriqMirabegron25$18,022
Potassium Citrate ErPotassium Citrate40$6,759
Gentamicin Sulfate26$2,886
Tamsulosin Hcl186$1,997
Finasteride48$910
Chlorthalidone33$853
Potassium Chloride27$724
Alfuzosin Hcl ErAlfuzosin Hcl21$518
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$361
Oxybutynin Chloride ErOxybutynin Chloride33$329
Ciprofloxacin Hcl41$197
Cephalexin29$125
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$88
Allopurinol11$81

Paid to pharmacies, not to this prescriber.

Other urology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →